Founded by Dr. Mark Roth of the Fred Hutchinson Cancer Center
Our origins are in innovation
We’ve harnessed the unique properties of iodide through our investigational product: FDY-5301
This easy-to-administer product has been shown in preclinical models to neutralize deleterious hydrogen peroxide produced during ischemia-reperfusion injury, resulting in reduced tissue damage, inflammation, and infarct size.
OUR MISSION:
Solving the reperfusion problem
Investigating sodium iodide as a novel approach for addressing ischemia-reperfusion injury (IRI)
intended to complement percutaneous coronary intervention (PCI) in the management of ST-elevation myocardial infarction (STEMI)
Our Pipeline
Learn about our development programs targeting unmet medical needs in acute conditions such as myocardial infarction and in chronic diseases such as cancer.
Our Phase 3
clinical trial
FDY-5301 is currently being evaluated in a Phase 3 clinical trial (Iocyte AMI-3) to assess its potential to reduce heart failure and cardiovascular death among patients suffering from an anterior STEMI
Learn more about Iocyte AMI-3 and see the promising results from Iocyte AMI, our completed Phase 2 clinical trial.
Recent News
Faraday Pharmaceuticals® Involved in Important Publication Exploring Iodine Redistribution During Trauma, Sepsis, and Hibernation and see the encouraging results from Iocyte AMI, our completed Phase 2 clinical trial for FDY-5301. READ MORE >